We are live on ! Find out more
ABBV icon

AbbVie

1,435 hedge funds and large institutions have $58B invested in AbbVie in 2013 Q4 according to their latest regulatory filings, with 192 funds opening new positions, 453 increasing their positions, 606 reducing their positions, and 38 closing their positions.

New
Increased
Maintained
Reduced
Closed

405% more first-time investments, than exits

New positions opened: 192 | Existing positions closed: 38

100% more call options, than puts

Call options by funds: $411M | Put options by funds: $206M

40% more funds holding in top 10

Funds holding in top 10: 4259 (+17)

18% more capital invested

Capital invested by funds: $49B → $58B (+$9.02B)

11% more funds holding

Funds holding: 1,2971,435 (+138)

0.05% less ownership

Funds ownership: 69.11%69.07% (-0.05%)

25% less repeat investments, than reductions

Existing positions increased: 453 | Existing positions reduced: 606

Holders
1,435
Holders Change
+138
Holders Change %
+10.64%
% of All Funds
41.49%
Holding in Top 10
59
Holding in Top 10 Change
+17
Holding in Top 10 Change %
+40.48%
% of All Funds
1.71%
New
192
Increased
453
Reduced
606
Closed
38
Calls
$411M
Puts
$206M
Net Calls
+$205M
Net Calls Change
+$19.5M

ABBV Hedge Fund Activity: Q4 2013 in Review

1,435 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q4 2013, worth a combined $58B — up 18% from $49B a quarter earlier.

Buyers outnumbered sellers: 192 funds opened new ABBV positions and 38 closed out — a net gain of 154 holders — while 453 added to existing stakes and 606 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $647M. The largest seller was Wellington Management Group, cutting an estimated $330M.

  • 1,435 institutional investors held AbbVie (ABBV) as of Q4 2013, up from 1,297 in Q3 2013.
  • Funds reported $58B of AbbVie stock for Q4 2013, up 18% quarter-over-quarter.
  • 192 funds opened new AbbVie positions in Q4 2013 and 38 closed out, a net change of +154 holders.
  • The largest AbbVie buyer in Q4 2013 was Fidelity Investments, an estimated $647M added.
  • The largest AbbVie seller in Q4 2013 was Wellington Management Group, an estimated $330M sold.

Based on aggregated 13F filings for Q4 2013.